Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show

Venetoclax Combo Safe, Effective in AML Patients Age 80 and Up, Real-World Data Show

— Study discovers survival is equivalent to that seen in more youthful clients in VIALE-A trial

Mike Bassett
Staff Writer, MedPage Today

Venetoclax (Venclexta) integrated with a hypomethylating representative (HMA)– the requirement of look after older clients with intense myeloid leukemia (AML)– seemed safe and reliable in clients in their 80s and 90s, a retrospective analysis revealed.

Typical total survival (OS) was 8.1 months amongst an overall of 154 clients with a mean age of 82 years (variety 80-92), and was 13.2 months amongst the 87 clients who attained an action, reported Justin Watts, MD, of the Sylvester Comprehensive Cancer Center at the University of Miami, and coworkers in Blood Neoplasia

With an average follow-up of 7.7 months, 23% of clients stayed in remission, with 20% still on treatment.

“There is definitely a subset of these clients who can be dealt with,” Watts informed MedPage Today“The action rates themselves– even in a high-risk population, and specifically in recently detected AML or de novo AML clients– did simply as well as more youthful clients performed in VIALE-AThey still react to treatment.”

“The concern is for how long they will react to treatment, and what is their survival,” he continued. “And about one-quarter of clients had actually lengthened survival, and those clients in whom there was a reaction might have rather long survival.”

The FDA authorized the mix of venetoclax with azacitidine, decitabine, or low-dose cytarabine in 2020 for the treatment of recently detected AML in grownups ages 75 and older or those unsuited to get extensive chemotherapy. Approval was based upon arise from the VIALE-A trial, in which typical OS increased from 9.6 months with azacitidine plus placebo to 14.7 months with the addition of venetoclax. Clients had a typical age of 76 years, and about 60% were 75 or older.

In describing the reasoning behind the existing research study, Watts and associates kept in mind that while making use of HMAs resulted in enhanced results, venetoclax integrated with HMAs supply a lot more of a chance for these older clients to increase survival– “if they can endure it.”

While much better endured than extensive chemotherapy, venetoclax plus HMAs can trigger substantial myelosuppression, in addition to transmittable and other non-infectious problems.

“The degree to which this might restrict its usage in a population of severe sophisticated age (>> 80 years) is not understood,” the authors composed, including that their research study is the very first to evaluate the tolerability and effectiveness of the mix in a solely octogenarian and nonagenarian population.

Watts and associates examined electronic medical records for 154 clients with AML treated with venetoclax plus HMAs for the very first time from March 2015 to April 2022 throughout 6 medical organizations in the U.S. and Italy.

Of the clients consisted of in the research study, 77% were freshly detected, 10% had actually fallen back or refractory AML, and illness status was unidentified in the staying 14%. Majority (53%) of clients had European LeukemiaNet 2017 negative danger AML, 33% had intermediate danger, 8% had beneficial threat, and 6% were unidentified.

Amongst freshly detected clients, 56% had actually freshly identified AML without previous myelodysplastic syndrome (MDS) or other myeloid neoplasm, and 44% had actually freshly detected AML with a history of previous MDS or other myeloid neoplasm.

In regards to how to dosage these clients, “it does appear a lower dosage is okay, even if they get less venetoclax,” Watts stated. “You can provide less treatment, since the treatment is really reliable, even when we provide it in much shorter periods.”

Two-thirds of clients began treatment with the basic dosage and treatment schedule, with 72% consequently customizing their venetoclax dosage or schedule after cycle 1.

Throughout the friend, clients were administered a last average venetoclax dosage of 400 mg for 21 days, duplicated every 35 days, and those clients who showed a treatment action got a last average venetoclax dosage of 200 mg for 21 days in 35-day cycles.

A much shorter last venetoclax period (≤ 14 days vs >> 14 days) was related to enhanced OS.

The mean follow-up of 7.7 months was a restriction of the research study, the authors acknowledged. They likewise pointed out that the average follow-up was 18.6 months for those still alive at information cutoff, “which highlights the significant reaction toughness in a subset of clients.”

In the whole client population, the total remission with insufficient count healing (CRc) rate was 57%, and the total action (CR) rate was 41%. In clients who had a reaction evaluation, the CRc rate was 63% and the CR rate was 46%.

For clients with freshly detected AML without previous MDS, 73% accomplished CR or CRc.

Beneficial danger AML, in addition to NPM1 and FLT3 anomalies were connected with better action rates, while clients with relapsed/refractory AML, prior MDS, prior HMA usage, TP53 anomalies, and complicated karyotype had lower action rates.

“And the security, even in this older client group who are going to be more frail and have more comorbidity, was rather comparable to VIALE-A in regards to 30- and 60-day death rates (8.5% and 17%, respectively),” Watts explained. “So, it is bearable in the majority of these clients.”

Treatment-emergent grade 3-4 anemia took place in 50% of clients, thrombocytopenia in 48%, neutropenia in 53%, and neutropenic fever in 46%. Death was credited to progression/relapse in 60% of cases.

Watts and associates stated even more research study is required to specify subsets of clients most likely to durably react (such as those with NPM1 IDH1/2, and RUNX1 anomalies) versus those who may take advantage of less venetoclax direct exposure (those with TP53 anomalies and previous MDS), in order to much better figure out how intensively to deal with octogenarians and nonagenarians with venetoclax and HMAs.

  • Mike Bassett is a personnel author concentrating on oncology and hematology. He is based in Massachusetts.


Watts reported advisory board/consulting functions with Servier, Rigel, Bristol Myers Squibb, Aptose Biosciences, Daiichi Sankyo, and Attivare Therapeutics, and research study assistance from Takeda, Rigel, and Immune System Key.

Numerous co-authors likewise reported relationships with market.

Main Source

Blood Neoplasia

Source Reference: Madarang E, et al “Venetoclax and hypomethylating representatives in octo- and nonagenarians with severe myeloid leukemia” Blood Neoplasia 2024; DOI: 10.1016/ j.bneo.2024.100016.

Find out more

Leave a Reply

Your email address will not be published. Required fields are marked *